Lakefront Biotherapeutics N.V.
Lakefront Biotherapeutics N.V.
- Market cap
- $2.18B
- P/E ratio
- 4.11
Your view on LKFT
Overview
What the company does, where it operates, and who runs it.
About Lakefront Biotherapeutics N.V.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Henry O. Gosebruch
- Headquarters
- SchaliEnhoevedreef 20 T, Mechelen, BE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Henry O. Gosebruch
- Headquarters
- SchaliEnhoevedreef 20 T, Mechelen, BE
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis.
The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Lakefront Biotherapeutics N.V.. Starting points for Lakefront Biotherapeutics N.V.: P/E 4.1, EPS $7.42, beta 0.12 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Lakefront Biotherapeutics N.V.. Trailing twelve-month EPS for Lakefront Biotherapeutics N.V. stands at $7.42. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Lakefront Biotherapeutics N.V.. Lakefront Biotherapeutics N.V. has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ELTXElicio Therapeutics, Inc. | Healthcare | NASDAQ | $27.6M | ||
| ELUTElutia Inc. | Healthcare | NASDAQ | $39.9M | ||
| ELVNEnliven Therapeutics, Inc. | Healthcare | NASDAQ | $3.4B | ||
| EMMAEmmaus Life Sciences, Inc. | Healthcare | OTC | $894,118 | ||
| ENDVEndonovo Therapeutics, Inc. | Healthcare | OTC | $31,875 | ||
| ENGNenGene Holdings Inc. | Healthcare | NASDAQ | $116.6M | ||
| ENGNWenGene Holdings Inc. Warrants | Healthcare | NASDAQ | $6.8M | ||
| ENLVEnlivex Therapeutics Ltd. | Healthcare | NASDAQ | $17.7M | ||
| ENP.AXEntropy Neurodynamics Limited | Healthcare | ASX | — | ||
| ENSCEnsysce Biosciences, Inc. | Healthcare | NASDAQ | $7.0M | ||
| ENTAEnanta Pharmaceuticals, Inc. | Healthcare | NASDAQ | $221.9M | ||
| ENTXEntera Bio Ltd. | Healthcare | NASDAQ | $575.5M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Lakefront Biotherapeutics N.V.. Coverage tracks Lakefront Biotherapeutics N.V. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Lakefront Biotherapeutics N.V.